Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

Brouwer-Visser: Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Fiaschi:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Deering:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Dhanik:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Cygan:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Zhang:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Jeong:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Pourpe:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Boucher:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Hamon:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Topp:Amgen, Boehringer Ingelheim, KITE, Regeneron, Roche: Research Funding; Amgen, KITE, Novartis, Regeneron, Roche: Consultancy. Bannerji:Sanofi-Pasteur: Other: Spouse is employee; AbbVie: Research Funding; F. Hoffmann-La Roche Ltd/Genentech, Inc and Pharmacyclics LLC, an AbbVie Company: Research Funding; Regeneron Pharmaceuticals: Research Funding. Duell:Morphosys: Research Funding. Advani:Celgene, Forty Seven, Inc., Genentech/Roche, Janssen Pharmaceutical, Kura, Merck, Millenium, Pharmacyclics, Regeneron, Seattle Genetics: Research Funding; Astra Zeneca, Bayer Healthcare Pharmaceuticals, Cell Medica, Celgene, Genentech/Roche, Gilead, KitePharma, Kyowa, Portola Pharmaceuticals, Sanofi, Seattle Genetics, Takeda: Consultancy. Flink:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Chaudhry:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Sirulnik:Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Murphy:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Weinreich:Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Yancopoulos:Regeneron Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Thurston:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Ambati:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company. Jankovic:Regeneron Pharmaceuticals, Inc: Current Employment, Current equity holder in publicly-traded company.The biomarker data described in the abstract will report on use of odronextamab in a Phase 1 clinical trial of patients with B-NHL